639858-44-9Relevant academic research and scientific papers
NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS
-
Page/Page column 304; 305; 306, (2017/08/20)
The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF- KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF
-
Page/Page column 152, (2008/06/13)
The present invention relates to a novel quinazoline derivative and a pharmaceutically acceptable salt thereof as a multiplex inhibitor, a method for the preparation thereof, and a pharmaceutical composition and a therapeutic composition comprising same as an active ingredient. The inventive quinazoline derivative as a multiplex inhibitor can selectively and effectively inhibit diseases caused by the overactivity of a tyrosine kinase.
Discovery and evaluation of N-cyclopropyl-2,4-difluoro-5-((2-(pyridin-2- ylamino)thiazol-5-ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2
Borzilleri, Robert M.,Bhide, Rajeev S.,Barrish, Joel C.,D'Arienzo, Celia J.,Derbin, George M.,Fargnoli, Joseph,Hunt, John T.,Jeyaseelan Sr., Robert,Kamath, Amrita,Kukral, Daniel W.,Marathe, Punit,Mortillo, Steve,Qian, Ligang,Tokarski, John S.,Wautlet, Barri S.,Zheng, Xiaoping,Lombardo, Louis J.
, p. 3766 - 3769 (2007/10/03)
Substituted 3-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)-amino)benzamides were identified as potent and selective inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2) kinase activity. The enzyme kinetics associated with the VEGFR-2 inhibi
Heterocyclic inhibitors of kinases
-
Page/Page column 9, (2008/06/13)
The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
